KPT-276

1 Cited Publications
Revisión del cliente

Based on 1 publication(s) in Google Scholar

KPT-276 is an orally active and blood-brain barrier-penetrant selective XPO1/CRM1 inhibitor. KPT-276 blocks XPO1-mediated nuclear export function and promotes nuclear retention of various tumor suppressor proteins. KPT-276 induces apoptosis and G1 cell cycle arrest in tumor cells, and downregulates c-MYC, CDC25A, and BRD4. KPT-276 reduces immune cell proliferation through nuclear accumulation of cell cycle inhibitors, rescues TDP-43 cytoplasmic mislocalization, and restores axon growth and growth rate in mutant PFN1 motor neurons. KPT-276 maintains axonal cytoskeletal integrity and mitochondrial function, and inhibits tumor growth. KPT-276 can be used for research on glioblastoma, non-Hodgkin lymphoma, amyotrophic lateral sclerosis, multiple myeloma, and non-small cell lung cancer.

Para uso exclusivo en investigación. No vendemos a pacientes.

  • Pureza : 99.94%
  • No. CAS: 1421919-75-6
  • Fòrmula: C16H10F8N4O
  • Peso molecular:426.26
  • Almacenamiento:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 2 years , -20°C, 1 year
  • Actividad biológica
  • Chemical Information
  • Solvente y solubilidad
  • Protocolo
  • Pureza y Documentación
  • Referencias
  • Help & FAQs

Publications Citing Use of MedChemExpress (MCE) KPT-276

More

Ver todos los productos específicos de isoformas Epigenetic Reader Domain

More

Ver todos los productos específicos de isoformas Interleukin Related

More
MOQ
Minimum order quantity
100 mg

Obtener un presupuesto En stock

Other size
Obtener un presupuesto
Please select quantity
Amount: USD 0.00